CliffBio
biologic

Herceptin

trastuzumab

Loss of exclusivityFebruary 2029projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameHerceptin
Active ingredienttrastuzumab
Strength150MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2017
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Herceptin patent cliff — loss of exclusivity February 2029 | CliffBio